Ritholtz Wealth Management cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 30.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,232 shares of the biopharmaceutical company’s stock after selling 538 shares during the period. Ritholtz Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $934,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the company. Orbimed Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $11,358,000. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $5,682,636,000. Contravisory Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $6,327,000. Compass Financial Management LLC lifted its stake in Regeneron Pharmaceuticals by 4,526.2% in the third quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock worth $2,280,000 after purchasing an additional 2,942 shares during the last quarter. Finally, Oxbow Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter worth $3,342,000. 83.31% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, Director Huda Y. Zoghbi sold 7,439 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,652,693.38. The trade was a 81.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Andrew J. Murphy sold 4,147 shares of the business’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. The trade was a 7.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,028 shares of company stock worth $25,025,950 over the last 90 days. Corporate insiders own 6.97% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on REGN. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Robert W. Baird lifted their price objective on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. Weiss Ratings raised Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 2nd. Finally, Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $898.97.
Regeneron Pharmaceuticals Stock Down 0.3%
Shares of Regeneron Pharmaceuticals stock opened at $952.40 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73. The company’s 50 day moving average price is $818.67 and its 200-day moving average price is $748.36. The stock has a market capitalization of $98.53 billion, a price-to-earnings ratio of 21.03, a P/E/G ratio of 1.26 and a beta of 0.10.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same period in the prior year, the business posted $11.83 EPS. The firm’s revenue was up 36.3% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.
Regeneron Pharmaceuticals Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Further Reading
- Five stocks we like better than Regeneron Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
